- Donate
- Understanding Rare Disease
- Living with a Rare Disease
- Community Support
- Advancing Research
- Driving Policy
- Get Involved
- Rare Disease News
- Resource Library
- About Us
- For Clinicians & Researchers
- For Patient Organizations
Last updated: 5/29/2024
Years published: 2020, 2024
NORD gratefully acknowledges Michael Levy, MD, PhD, Associate Professor, Harvard Medical School; Director, Neuromyelitis Optica Clinic and Research Laboratory; Research Director, Division of Neuroimmunology & Neuroinfectious Disease; Massachusetts General Hospital and the Superficial Siderosis Research Alliance, for the preparation of this report.
Summary
Superficial siderosis is a disabling degenerative disorder affecting the brain and spinal cord. Persistent or recurring long-term bleeding (hemorrhage) into the subarachnoid space in the brain results in a toxic build-up of hemosiderin (an important component of iron delivery) on the surface of the brain and pia mater from circulating cerebrospinal fluid. Patients have one or more of the classic three symptoms: hearing loss, movement abnormalities (ataxia) and motor difficulties due to suspected spinal cord injury (myelopathy) with pyramidal signs. Proper recognition and timely early diagnosis of superficial siderosis allow for early care planning.
Typically, the period between the onset of noticeable clinical symptoms and the trigger event ranges between 10-30 years. Symptoms and signs will present depending on the location of hemosiderin deposition and state of weakness of neural tissue. The intensity of deposition shown on imaging will not always correspond with the degree of disability due to the slow-moving progressive nature of the disorder. About 95% of patients have progressive hearing impairment in both ears and about 88% of patients show signs of progressive ataxia with a focus on wide-based gait and balance issues. About 76% have myelopathy with pyramidal signs. Additional signs include mild cognitive impairment, uncontrolled eye movements (nystagmus), poor coordination (dysmetria), difficulty swallowing (dysphagia), uncontrolled muscle movements (spasticity), loss of smell (anosmia), loss of taste (ageusia), different pupil sizes in the eyes (anisocoria), bladder or bowel dysfunction, sensory defects, small motor dysfunction, nerve pain (neuropathy), headache, autonomic nervous system dysfunction, inability to perform rapid, coordinated movements (dysdiadochokinesia), slurred speech (dysarthria), overactive reflexes (hyperreflexia) and abnormal foot reflexes (Babinski signs)
Cortical superficial siderosis (cSS) is a recognized type of superficial siderosis. Hemosiderin deposition is limited to cortical sulci over the convexities of the cerebral hemispheres, sparing the cerebellum, brainstem and spinal cord affected in the classic iSS symptoms. Identified with gradient recalled echo (GRE) or susceptibility-weighted imaging (SWI) MRI as linear hypointensities, cortical superficial siderosis (cSS) is often due to cerebral amyloid angiopathy, an age-related cerebral small vessel disorder. Symptoms of amyloid angiopathy include transient focal neurological episodes, cognitive impairment, generalized seizures, headaches and increased intracerebral hemorrhage risk.
Superficial siderosis is an acquired disorder caused by chronic long-term subarachnoid bleeding. A large percentage of the identifiable bleed sources are abnormalities resulting from recurring brain bleeds (chronic suboccipital hematomas), sacs protruding from the spinal column (meningoceles) or spinal surgery tears resulting in pseudomeningoceles. Other causes include root avulsions or epidural cyst removal, intradural cranial surgery, brain tumors, vascular abnormalities, fragile capillary regrowth after brain surgery, nerve damage (brachial plexus injury), head injury or bone marrow exposed to the spinal (intrathecal) space.
Ruptured blood cells (hemolysis) in the cerebrospinal fluid create a heme overload that triggers Bergman glia and microglial cells into producing the enzyme heme oxygenase-1. HO-1 breaks down the heme molecule resulting in the release of free-iron molecules, carbon dioxide and biliverdin. Astrocytes release ferritin proteins to curb the free-iron molecules and the product is hemosiderin. Because hemosiderin is not soluble, gravity pulls it to the subpial surfaces in the infratentorium and spinal column where it attaches to the pia mater. Sleeping in the supine position leads to large accumulations in the cerebellum. Cranial nerve sections, brainstem and the spinal cord may also become encased in hemosiderin. Long-term exposure to free-iron molecules released from the hemosiderin layer is toxic to the underlying neural tissue.
Superficial siderosis affects all races and age groups, with males affected three times more often than females. The prevalence of superficial siderosis is estimated to be 1 in one million individuals. As of 2024, there are an estimated 300 diagnosed cases in the U.S. Diagnoses are increasing due to improved MRI techniques and neuro-radiologist awareness. The actual incidence of superficial siderosis is suspected to affect a larger population than is currently diagnosed.
The average time from the clinical manifestation of early symptoms such as ringing of the ears (tinnitus), complaints of dizziness, or reports of phantom odors to the diagnosis of superficial siderosis may be as long as 17 years, partly due to the slow progression of the disease. Clinical investigation of patient complaints should be reviewed against the long-term medical history focusing on previous surgical procedures, aneurysm, traumatic contusions or accidents occurring as long as thirty to forty years in the past with older patients.
MRI sequencing is required to confirm the diagnosis. Superficial siderosis is characterized as a rim of low signal covering the subpial surfaces of the brain, brainstem and spinal cord, particularly on the gradient-echo (GRE) or susceptibility-weighted (SWI) sequences. Ependymal hypointensity may also occur in severe forms of superficial siderosis.
The first step after a diagnosis is determining if a bleed source is present. A cause is not identified for a large percentage of patients. A CT myelogram is the preferred method to determine the location of a suspected bleed due to dural defect. The three suggested approaches for stopping a bleed are injection of fibrin glue into the dural tear site; for small leaks, an epidural blood patch may pull the dura from surrounding bone and immobilize the spinal cord long enough for healing to take place. Surgical closure of dural defects or other active bleed sites offers the best opportunity to stop additional hemosiderin deposition.
The progression of neurological deficits will continue as long as free-iron molecules continue to release from existing hemosiderin. Elimination of hemosiderin deposition off the subpial surface is fundamental to potentially stopping cerebellar atrophy and neural damage. This removal action must be accomplished through iron chelation. For a chelating agent to achieve its desired pharmacological effect, the drug must reach the target sites at sufficient concentration. Deferiprone is an orally active bidentate hydroxypyridinone iron chelator proven to cross the blood-brain barrier that binds to ferric ions (fe3+), forms a 3:1 chelator to iron stable complex, and is eliminated through urine. One reason for the limited efficacy of deferiprone in clinical use is its extensive metabolism in the liver. Patients prescribed deferiprone require close monitoring due to the severe nature of possible side effects, most notably being a low incidence of reversible agranulocytosis.
Patient care will rely on the coordinated treatment of the underlying symptoms through referral to appropriate specialties. The superficial siderosis patient in mid to late-stage progression lives in a state of compromised neurological reserve on a perpetual basis. They may require a longer than average recovery time from procedures, surgery or illness. Consideration should be given for neuropsychological evaluation with increasing patterns of cognitive and social impairment, memory problems or behavioral changes. About 20% of patients diagnosed with mild or progressive cognitive impairment initially may progress to neurodegenerative dementia.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website: https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, contact:
www.centerwatch.com
For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
Albayram MS, Smith G, Tufan F, Weiss MD. Frequency, extent, and correlates of superficial siderosis and ependymal siderosis in premature infants with germinal matrix hemorrhage: an SWI study. AJNR Am J Neuroradiol. 2020;41(2):331-337.
Charidimou A, Boulouis G, Xiong L, et al. Cortical superficial siderosis evolution. Stroke. 2019;50(4):954-962. doi:10.1161/STROKEAHA.118.023368
Zhou C, Liu K, Yan S, Jin Y. Association between cortical superficial siderosis and dementia in patients with cognitive impairment: a meta-analysis. Front Neurol. 2019;10:8. Published 2019 Jan 29. doi:10.3389/fneur.2019.00008
Kessler RA, Li X, Schwartz K, Huang H, Mealy MA, Levy M. Two-year observational study of Deferiprone in superficial siderosis. CNS Neurosci Ther. 2018;24(3):187–92.
Del Bigio M and Phillips S. Retroocular and subdural hemorrhage or hemosiderin deposits in pediatric autopsies. Journal of Neuropathology & Experimental Neurology. 2017; 76. 10.1093/jnen/nlx010.
Inoue Y, Nakajima M, Uetani H, et al. Diagnostic significance of cortical superficial siderosis for Alzheimer disease in patients with cognitive impairment. American Journal of Neuroradiology 2016; 37 (2) 223-227.
Brinker T, Stopa E, Morrison J, & Klinge P. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014 May 1;11:10. doi: 10.1186/2045-8118-11-10.
Zonneveld HI, Goos JD, Wattjes MP, et al. Prevalence of cortical superficial siderosis in a memory clinic population. Neurology. 2014;82(8):698-704. doi:10.1212/WNL.0000000000000150
Kumar N, Lane JI, Piepgras DG. Superficial siderosis: sealing the defect. Neurology, 2009;72:671–673.
Le Scanff J, Vighetto A, Gédéon C, Bonnefoy M, & Krolak-Salmon P. Superficial siderosis revealed by isolated cognitive impairment. J Gerontol A Biol Sci Med Sci. 2009 Mar;64(3):385-7.
Koeppen AH, Michael SC, Li D, Chen Z, Cusack MJ, Gibson WM, et al. The pathology of superficial siderosis of the central nervous system. Acta neuropathologica. 2008;116(4):371.
Swartz JD. Pathology of the vestibulocochlear nerve. Neuroimaging Clin. N. Am. 2008;18 (2): 321-46.
Kumar N. Superficial Siderosis: associations and therapeutic implications. Arch Neurol. 2007;64(4):491–496.
Levy M, Turtzo C, Llinas RH. Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol. 2007;3(1):54-59. doi:10.1038/ncpneuro0356
Kumar N, Lindell EP, Wilden JA, Davis DH. Role of dynamic CT myelography in identifying the etiology of superficial siderosis. Neurology 2005;65:486–488.
Glasier CM, Garcia-Thomas GI, Allison JW Superficial CNS siderosis in the newborn: MR diagnosis. Pediatr Radiol 1999;29:76–77.
Bonito V, Agostinis C, Ferraresi S, Defanti CA. Superficial siderosis of the central nervous system after brachial plexus injury. Case report. J Neurosurg. 1994;80(5):931-934. doi:10.3171/jns.1994.80.5.0931
Koeppen AH, Dickson AC, Chu RC, Thach RE. The pathogenesis of superficial siderosis of the central nervous system. Ann Neurol, 1993;34:646–653.
NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/